Nystatin prophylaxis in immunocompromised children.
In conclusion, the use of nystatin for fungal prophylaxis in hematology/oncology/bone marrow transplantation patients appears to convey little or no benefit over no therapy. Nystatin treatment significantly reduced the frequency of multiple-site colonization and of persistently positive oropharyngeal cultures, but was not able to prevent the occurrence of disseminated fungal infections. Other antifungal agents (e.g., ketoconazole, fluconazole, itraconazole, oral or intravenous amphotericin B) may be of benefit. Studies comparing nystatin with other agents are available in the literature but are beyond the scope of this review.
Taylor
T L
TL
Pharmacy Department, Hospital for Sick Children, Toronto, Ontario, Canada.
D000380:Agranulocytosis / Q000150:complications; D000935:Antifungal Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002177:Candidiasis / Q000209:etiology / Q000517:prevention & control*; D002648:Child; D006801:Humans; D016867:Immunocompromised Host; D007938:Leukemia / Q000150:complications; D009761:Nystatin / Q000627:therapeutic use*
D000935:Antifungal Agents; D009761:Nystatin